Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
暂无分享,去创建一个
M. Ratain | R. Bies | F. Innocenti | J. Ramírez | R. Mathijssen | R. V. van Schaik | E. Tsakalozou | G. Toffoli | A. Forrest | A. Etheridge | E. Cecchin | S. Karas
[1] R. Mathijssen,et al. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics , 2018, Clinical Pharmacokinetics.
[2] F. Innocenti,et al. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer , 2016, Clinical Cancer Research.
[3] Soma Das,et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Andrew C. Hooker,et al. PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool , 2012, Comput. Methods Programs Biomed..
[5] M. Baiget,et al. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer , 2011, British Journal of Cancer.
[6] F. Innocenti,et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Wiemer,et al. A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan , 2010, Clinical Cancer Research.
[8] Soma Das,et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Leon Aarons,et al. An Effective Approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.
[10] M. Ratain,et al. Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet? , 2008, Pharmacotherapy.
[11] F. Pinguet,et al. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. , 2007, Oncology reports.
[12] Teruhiko Yoshida,et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.
[13] J. Verweij,et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. , 2006, The oncologist.
[14] Giuseppe Toffoli,et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Goldberg,et al. Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction , 2006, Clinical Cancer Research.
[16] E. Shin,et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] David Z. D'Argenio,et al. Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[18] J. Verweij,et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. , 2004, Journal of the National Cancer Institute.
[19] Soma Das,et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Foracchia,et al. POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..
[21] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[22] J. Robert,et al. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan , 2004, Cancer Chemotherapy and Pharmacology.
[23] P. Adamson,et al. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] C. Fuchs,et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Mark J Ratain,et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN‐38 and SN‐38 glucuronide , 2002, Clinical pharmacology and therapeutics.
[26] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapy.
[27] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Verweij,et al. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38 , 2002, British Journal of Cancer.
[29] M. Ratain. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[31] R. Goldberg,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[32] H. Saka,et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.
[33] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[34] C. V. Pesheck,et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[35] J. Verweij,et al. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin. , 1999, Anti-cancer drugs.
[36] J. Verweij,et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] N. Kemeny,et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Hérait,et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Ratain,et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] H. Ohmatsu,et al. Efficient Sampling Strategies for Forecasting Pharmacokinetic Parameters of Irinotecan (CPT‐11): Implication for Area Under the Concentration‐Time Curve Monitoring , 1995, Therapeutic drug monitoring.
[41] S. Culine,et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] N. Saijo,et al. A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[43] K. Eguchi,et al. A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[44] P. Hérait,et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Culine,et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.
[46] P. Bosma,et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. , 1994, The Journal of biological chemistry.
[47] L. Grochow,et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.
[48] G. Weiss,et al. Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Boehm,et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .
[50] D Z D'Argenio,et al. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.
[51] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[52] H. Akaike. A new look at the statistical model identification , 1974 .